Study on adverse reactions and influencing factors of two kinds of docetaxel combined with cyclophosphamide for the treatment of breast cancer

Xing Xueting; Ding Weijie; Zhang Ruomei; Lei Ying; Zhang Xiaoqing

doi:10.3760/j.issn.1673-4777.2023.12.013

Abstract：Objective To investigate the occurrence of adverse drug reaction(ADR)in breast cancer patients receiving cyclophosphamide in combination with domestic and imported docetaxel and to analyze the influencing factors.Methods Totally 200 patients with breast cancer treated with chemotherapy from January 2020 to December 2022 were selected retrospectively in the International Peace Maternity and Child Health Hospital,School of Medicine,Shanghai Jiao Tong University.Patients were divided into Dopafei group(100 cases)and Taxotere group(100 cases)according to the use of domestic or imported docetaxel.Dopafei group was given Dopafei(domestic docetaxel)combined with cyclophosphamide chemotherapy,and Taxotere group was given Taxotere(imported docetaxel)combined with cyclophosphamide chemotherapy,all for 4 or 6 courses.ADR in patients and the influencing factors were analyzed.Results There were no significant differences in the rate of ADR between the two groups(all P＞0.05).After treatment,haemoglobin,white blood cell count,and neutrophil count in Taxotere group were lower than those in Dopafei group,and platelet count,serum creatinine,alanine aminotransferase,and aspartate aminotransferase levels in Taxotere group were higher than those in Dopafei group,while the differences between the two groups were not significantly statistical(all P＞0.05).Multivariate analysis showed that body mass index(odds ratio=0.416,95％confidence interval:0.193-0.900,P=0.026)was an independent influencing factor for the occurrence of ADR from docetaxel.Conclusions Both domestic and imported docetaxel can cause ADR such as bone marrow suppression and liver and kidney function damage.There is no significant difference in safety between the two drugs.In addition,for breast cancer patients with low body mass index during chemotherapy,drug monitoring should be strengthened to avoid or reduce ADR caused by docetaxel.